<code id='A94EA490FC'></code><style id='A94EA490FC'></style>
    • <acronym id='A94EA490FC'></acronym>
      <center id='A94EA490FC'><center id='A94EA490FC'><tfoot id='A94EA490FC'></tfoot></center><abbr id='A94EA490FC'><dir id='A94EA490FC'><tfoot id='A94EA490FC'></tfoot><noframes id='A94EA490FC'>

    • <optgroup id='A94EA490FC'><strike id='A94EA490FC'><sup id='A94EA490FC'></sup></strike><code id='A94EA490FC'></code></optgroup>
        1. <b id='A94EA490FC'><label id='A94EA490FC'><select id='A94EA490FC'><dt id='A94EA490FC'><span id='A94EA490FC'></span></dt></select></label></b><u id='A94EA490FC'></u>
          <i id='A94EA490FC'><strike id='A94EA490FC'><tt id='A94EA490FC'><pre id='A94EA490FC'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          comprehensive

          author:comprehensive    - browse:318
          Checkpoint inhibitor
          Adobe

          ITeos Therapeutics offered the first look at clinical data for its experimental cancer antibody that works by blocking the novel — and very buzzworthy — protein target called TIGIT.

          The tumor-shrinking activity of the company’s drug, called EOS-448, was minimal but still comparable to early study data from competing TIGIT-targeted drugs in development, including ones from Roche and Merck.

          advertisement

          iTeos presented the EOS-448 Phase 1 study results at the annual meeting of the American Association for Cancer Research on Saturday.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          leisure time